7th SEEM: repeat biopsies of the prostate
Thursday, 20 October 2011- A Serbian study won the third prize from Richard Wolf for the best abstract presentation at the recent EAU 7th South Eastern European Meeting (SEEM) held in Skopje.
Below is the original abstract submitted by winners V. Andrejevic and colleagues:
Abstract S33: Repeat biopsies of prostate- our experience
Authors: Crnomarkovic D.1, Andrejevic V.2, Sekulic S.3, Glisic B.4, Nedec N.5, Micic M.6
1Urological Clinic, Dept. of Oncology, Belgrade, Serbia, 2Urological Clinic, Dept.
of Intesive Care, Belgrade, Serbia, 3Medical Center of Loznica, Dept. of Urology,
Loznica, Serbia, 4Urological Clinic, Dept. of Medical Biochemistri, Belgrade,
Serbia, 5Urological Clinic, Dept. of Farmacology, Belgrade, Serbia, 6Urological
Clinic, Dept. of Andrology, Belgrade, Serbia
Introduction & Objectives: According to the PSA level, digital rectal examination and ultra sound examination, we performed prostate biopsy in men. In patients whose biopsy specimens were negative for prostate cancer we conducted a repeat biopsy. We also aim to determinate the differences between groups with positive and negative biopsy samples for prostate cancer after secondary biopsy.
Material & Methods: In the period 2006-2010 in our clinic 720 patients underwent transrectal ultra sound guided sextant biopsy. 324 (45%) patients were negative for prostate cancer, of those patients 162 underwent secondary biopsy after 6 to 8 weeks. We compared the difference between the group with positive and a group with negative for prostate cancer samples after secondary biopsy.
Results: In 42 (26%) cases secondary biopsy samples were positive for prostate cancer, but 120 (74%) cases were negative. Difference in: age 73±7 Vs. 65±7; PSA 27.2±15.6 vs. 7.2±5.2; f/TPSA 0.13±0.01 Vs. 0.38±0.21; PSAD 0.38±0.31 vs. 0.12±0.07; for secondary biopsi positive Vs. negative group for prostate cancer, respectively were significant (p<0.01).
Conclusions: All examined parameters: age, PSA and other derivates, singly and together, to show on secondary biopsy whether it will be positive or negative for prostate cancer. This may help to inform whether to perform secondary biopsy or not.
Source: Poster Session 2, BPH, Prostate Cancer, EAU 7th South Eastern European Meeting (SEEM), 14-15 October 2011, Skopje. European Urology Supplements, Vol. 10, Issue 9, October 2011.